{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:43:38Z","timestamp":1763059418749,"version":"build-2065373602"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>There exists a significant care gap in the diagnosis, treatment, and management of inflammatory bowel diseases (IBD) in Latin America compared to the United States and Europe. This review aims to assess the clinical effectiveness of advanced therapies for patients with moderate to severe ulcerative colitis (UC) and Crohn\u2019s disease (CD) in Latin America. We conducted a targeted literature review of studies reporting clinical outcomes of advanced IBD therapies in Latin American countries. After applying pre-defined inclusion and exclusion criteria, 14 articles were included. Data were extracted regarding patient populations, therapeutic agents, clinical outcomes, and geographic distribution. The majority of studies focused on biologic therapies, including adalimumab, infliximab, ustekinumab, and vedolizumab. These therapies demonstrated favorable clinical remission and response rates in Brazil, Argentina, Mexico, and Colombia for both UC and CD. Reported outcomes were largely consistent with observational data from North America and Europe, supporting the generalizability of therapeutic efficacy across regions. Advanced therapies for IBD appear to be effective in Latin American populations, with clinical outcomes comparable to those reported globally. Increasing access to these treatments may improve patient outcomes, reduce disease burden, and potentially decrease long-term healthcare costs in the region.<\/jats:p>","DOI":"10.1177\/17562848251383799","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T04:51:18Z","timestamp":1759726278000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A targeted review of clinical outcomes of advanced IBD therapies in Latin America"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6201-7515","authenticated-orcid":false,"given":"Ieshaan S.","family":"Kumar","sequence":"first","affiliation":[{"name":"The Pingry School, Basking Ridge, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-8441","authenticated-orcid":false,"given":"Rahul S.","family":"Dalal","sequence":"additional","affiliation":[{"name":"Harvard Medical School, 850 Boylston Street, Suite 201, Chestnut Hill, MA 02467, USA"},{"name":"Crohn\u2019s and Colitis Center, Brigham and Women\u2019s Hospital, Boston, MA, USA"},{"name":"Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804647"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231207312"},{"issue":"1","key":"e_1_3_5_4_2","first-page":"46","article-title":"Diagnosis and treatment of inflammatory bowel disease: first Latin American Consensus of the Pan American Crohn\u2019s and Colitis Organisation","volume":"82","author":"Yamamoto-Furusho JK","year":"2017","unstructured":"Yamamoto-Furusho JK, Bosques-Padilla F, de-Paula J, et al. Diagnosis and treatment of inflammatory bowel disease: first Latin American Consensus of the Pan American Crohn\u2019s and Colitis Organisation. Rev Gastroenterol Mex 2017; 82(1): 46\u201384.","journal-title":"Rev Gastroenterol Mex"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231167953"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i4.1197"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.06.030"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-2803.202000000-77"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i8.1330"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02341-7"},{"issue":"3","key":"e_1_3_5_11_2","first-page":"241","article-title":"Adalimumab in the induction of Crohn\u2019s disease remission: results of a Brazilian multicenter case series","volume":"31","author":"Kotze PG","year":"2011","unstructured":"Kotze PG, Vieira A, Miranda EF, et al. Adalimumab in the induction of Crohn\u2019s disease remission: results of a Brazilian multicenter case series. J Coloproctol (Rio J) 2011; 31(3): 241\u2013246.","journal-title":"J Coloproctol (Rio J)"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032014000100009"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-2803.201700000-51"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1789223"},{"issue":"1","key":"e_1_3_5_15_2","first-page":"2022","article-title":"Effectiveness and safety of tofacitinib in the management of ulcerative colitis: a Brazilian observational multicentric study","volume":"360","author":"Perin RL","unstructured":"Perin RL, Magro DO, Andrade AR, et al. Effectiveness and safety of tofacitinib in the management of ulcerative colitis: a Brazilian observational multicentric study. Crohn\u2019s Colitis 360 2022; 5(1): otac050.","journal-title":"Crohn\u2019s Colitis"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-2803.202204000-89"},{"issue":"2","key":"e_1_3_5_17_2","first-page":"2024","article-title":"Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study","volume":"360","author":"Parra RS","unstructured":"Parra RS, Chebli JMF, de Azevedo MFC, et al. Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study. Crohn\u2019s Colitis 360 2024; 6(2): otae023.","journal-title":"Crohn\u2019s Colitis"},{"issue":"4","key":"e_1_3_5_18_2","first-page":"2023","article-title":"Vedolizumab in mild-to-moderate Crohn\u2019s disease patients na\u00efve to biological therapy: a multicentric observational study","volume":"360","author":"Dotti AZ","unstructured":"Dotti AZ, Magro DO, Vilela EG, et al. Vedolizumab in mild-to-moderate Crohn\u2019s disease patients na\u00efve to biological therapy: a multicentric observational study. Crohn\u2019s Colitis 360 2023; 5(4): otad053.","journal-title":"Crohn\u2019s Colitis"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-2803.201900000-58"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2022.11.006"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2023.04.002"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000355529"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2024.01.009"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00284-4"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.08.020"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00033"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.01.181"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28907-3"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31829936c2"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002047"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad043"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028624"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12841"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14334"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2019-101288"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30012-1"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0162-0"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251383799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251383799","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251383799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T07:16:07Z","timestamp":1759907767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251383799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"alternative-id":["10.1177\/17562848251383799"],"URL":"https:\/\/doi.org\/10.1177\/17562848251383799","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17562848251383799"}}